E-viri
Recenzirano
Odprti dostop
-
Reekie, Joanne; Stovring, Henrik; Nielsen, Henrik; Johansen, Isik S.; Benfield, Thomas; Wiese, Lothar; Stærke, Nina Breinholt; Iversen, Kasper; Mustafa, Ahmed Basim; Petersen, Kristine Toft; Juhl, Maria Ruwald; Knudsen, Lene Surland; Iversen, Mette Brouw; Andersen, Sidsel Dahl; Larsen, Fredrikke Dam; Baerends, Eva Anna Marianne; Lindvig, Susan Olaf; Rasmussen, Line Dahlerup; Madsen, Lone Wulff; Bannister, Wendy; Jensen, Tomas Oestergaard; Dietz, Lisa Loksø; Ostrowski, Sisse Rye; Østergaard, Lars; Tolstrup, Martin; Lundgren, Jens D.; Søgaard, Ole Schmeltz
International journal of infectious diseases, September 2024, Letnik: 146Journal Article
•Hybrid-immunity (both vaccine induced and natural immunity) to SARS-CoV-2 is common.•Hybrid-immunity has an important impact on the antibody trajectories.•More antibodies were seen in people with hybrid compared to vaccine-only immunity.•Antibodies declined slower in people with hybrid compared to vaccine-only immunity.•People with comorbidities had lower antibody levels independent of hybrid-immunity. This study aimed to compare antibody trajectories among individuals with SARS-CoV-2 hybrid and vaccine-induced immunity. Danish adults receiving three doses of BTN162b2 or mRNA-1237 were included prior to first vaccination (Day 0). SARS-CoV-2 anti-spike IgG levels were assessed before each vaccine dose, at Day 90, Day 180, 28 days after 3rd vaccination (Day 251), Day 365, and prior to 4th vaccination (Day 535). SARS-CoV-2 PCR results were extracted from the national microbiology database. Mixed-effect multivariable linear regression investigated the impact of hybrid-immunity (stratified into 4 groups: no hybrid immunity, PCR+ prior to 3rd dose, PCR+ after 3rd dose and before Day 365, PCR+ after Day 365) on anti-spike IgG trajectories. A total of 4,936 individuals were included, 47% developed hybrid-immunity. Anti-spike IgG increases were observed in all groups at Day 251, with the highest levels in those PCR+ prior to 3rd dose (Geometric Mean; 535,647AU/mL vs. 374,665AU/mL with no hybrid-immunity, P<0.0001). Further increases were observed in participants who developed hybrid immunity after their 3rd dose. Anti-spike IgG levels declined from Day 251-535 in individuals without hybrid-immunity and in those who developed hybrid-immunity prior to their 3rd dose, with lower rate of decline in those with hybrid-immunity. Hybrid-immunity results in higher and more durable antibody trajectories in vaccinated individuals.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.